The case for & against
Bull & Bear analysis
Bullish
STAAR Surgical Company (NASDAQ: STAA) specializes in vision correction through innovative intraocular lens (ICL) technologies. As a leader in the refractive surgery market, the company focuses on advancing its EVO ICL product to meet the rising global demand for corrective vision solutions, particularly in the context of increasing myopia prevalence. STAAR Surgical is strategically positioned to leverage opportunities in both the U.S. and China, catering to an evolving consumer base looking for less invasive surgical options.
Bull says
- ↑Q1 2026 net sales up 119.6% YoY to $93.5M, led by U.S. and China demand.
- ↑Adjusted EBITDA turned positive at $24.4M in Q1 2026 versus a $26.3M loss year-ago; gross margin improved to 73.6%.
- ↑Ended Q1 with $163.9M cash and zero debt, supporting growth initiatives.
- ↑EVO Plus ICL launch in China exceeded initial forecasts, expanding refractive surgery market share.
- ↑Improving Chinese consumer confidence and supportive policies may drive further sales growth.
- ↑Strong profitability revisions and high liquidity underpin favorable long-term outlook.
Bear says
- ↓Reported $80.45M net loss in 2025, signaling sustained margin pressures.
- ↓China sales plunged to $0.39M in Q1 2025 from $38.5M, reflecting high market volatility.
- ↓Management withdrew formal guidance amid macro uncertainty, dampening investor confidence.
- ↓New competitors like iBright and pricing pressure from incumbents threaten market position.
- ↓Negative earnings yield indicates current valuation may not reflect sustainable profitability.
- ↓Elevated leverage risk and weak growth trends may limit upside potential.
Investment themes with STAA
Health Care Equipment & Supplies↑ +0.40%
Clinical instruments and devices powering patient care
ABT · ISRG · SYK
Most Shorted Stocks↑ +0.54%
Stocks with highest short interest
LITE · FSLY · SPHR
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 05-14-2026neutral
Transcript signals
Bull points
- We remain optimistic, particularly in the long-term value of this business from a growth opportunity standpoint.
- 22-plus percent growth there coming off of a strong growth last year, and that number is now becoming a more respectable number.
- We expect to have a good Q2, as it is the beginning of the, you know, busy summer season.
Bear points
- as a result, our ex-China growth was only 6%.
- You know, the whole world's under pressure relative to pricing.
- China net sales were 47.4 million in the first quarter, driven by the commercial launch of Vivo+, and continued demand for EVO.
Read full transcript analysis ›